Overview
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Eligibility
- Inclusion Criteria
- Participants from Study AMAC (NCT02589665) or AMBG (NCT03524092) who have had at least one study drug administration and have not had early termination of study drug.
- Female participants must agree to contraception requirements.
- Exclusion Criteria
- Participants must not have developed a new condition, including cancer in the
originator study.
- Participants must not have any important infections including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during either originator study
- Participants may not have received surgery for UC in the originator study or are likely to require surgery for treatment of UC during the study.
- Participants must not have developed adenomatous polyps during the originator study that have not been removed prior to the start of this study.